Boston Scientific (BSX) Misses Q4 EPS by 2c; Guides

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.45, $0.02 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $3.24 billion versus the consensus estimate of $3.24 billion.

GUIDANCE:

Boston Scientific sees Q1 2023 EPS of $0.42-$0.44, versus the consensus of $0.44.

Boston Scientific sees FY2023 EPS of $1.86-$1.93, versus the consensus of $1.93.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• New leader board: Citi refreshes AI compute semiconductor picks
• Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes
• Applied Materials (AMAT) PT Raised to $850 at Cantor Fitzgerald: Limited EPS Upside